Country
Clinical Trials in Mozambique
Studies with at least one site in Mozambique. Open a trial for its sites in Mozambique, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 21Tuberculosis, Diagnostics
Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)
Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years.
- Conditions
- Tuberculosis, Diagnostics, Global Health
- Trial name
- NCT05989802
- Testing
- Oral swab molecular testing, Automated Cough Sound Analysis, Automated Lung Sound Analysis
- Where
- 3 sites in Mozambique, South Africa and 1 more
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Cervical Cancer
Rice Technologies for Cervical Cancer Screening and Diagnosis
The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to…
- Trial name
- NCT05372484
- Testing
- Multimodal optical imaging
- Where
- 4 sites in United States, Mozambique
- Volunteers
- 678 people
- Sponsor
- M.D. Anderson Cancer Center
Infectious Disease, Febrile Illness
A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)
The overall aim of the study is to provide evidence that introducing novel biomarkers evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and…
- Conditions
- Infectious Disease, Febrile Illness, Child, Only
- Trial name
- NCT06422338
- Testing
- IMCI-enhanced by suPAR levels (SoC + suPAR POC)
- Where
- 2 sites in Gabon, Mozambique
- Volunteers
- 5,212 people
- Sponsor
- Barcelona Institute for Global Health
HIV-1-infection
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
- Trial name
- ELDORADO (NCT06203132)
- Testing
- Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine
- Where
- 19 sites in Brazil, Cameroon and 4 more
- Volunteers
- 610 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Human Papilloma Virus Related Cervical Carcinoma
The Women's Screening and Self-Testing Program (PROMETA) Study
This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within…
- Trial name
- PROMETA (NCT06810739)
- Testing
- HPV DNA testing be self-collected vaginal swab
- Where
- Mozambique
- Volunteers
- 8,445 people
- Sponsor
- Tulane University
Group B Streptococcus, Invasive Bacterial Diseases (IBD)
Preparing for Maternal GBS Vaccine Trials in Africa
Infections are one of the key causes of newborn deaths. Among them, Group B Streptococcus (GBS) is the leading cause of sepsis and bacterial meningitis in the first 90 days of life.
- Conditions
- Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization
- Trial name
- PROTECT (NCT06833957)
- Where
- 10 sites in Kenya, Malawi and 2 more
- Volunteers
- 18,100 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Abortion, Second Trimester, Abortion, Medical
Foley Balloon for Cervical Preparation Before Dilation and Evacuation
To evaluate the Foley Balloon technique for cervical preparation before second trimester surgical abortion between 16 and 21 weeks estimated gestational age in combination with misoprostol to prepare the cervix before dilation…
- Trial name
- NCT06850974
- Testing
- Foley Balloon Catheter, Misoprostol, Laminaria
- Where
- Mozambique
- Volunteers
- 102 people
- Sponsor
- Stony Brook University
Infectious Disease, Infections
L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)
In low and middle-income countries, children admitted to hospital are not similarly ill, and do not all have a comparable prognosis.
- Conditions
- Infectious Disease, Infections, Child, Only
- Trial name
- NCT06426147
- Testing
- L-citrulline
- Where
- 2 sites in Ethiopia, Mozambique
- Volunteers
- 2,200 people
- Sponsor
- Barcelona Institute for Global Health
Tuberculosis, Tuberculosis (TB)
Questioning the Epidemiology of Asymptomatic TB
Tuberculosis (TB) remains one of the world's leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the…
- Conditions
- Tuberculosis, Tuberculosis (TB), HIV, HIV (Human Immunodeficiency Virus)
- Trial name
- TB QUEST (NCT07312266)
- Where
- Mozambique
- Volunteers
- 6,770 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Completed, with results posted
All 22HIV Infections
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
The purpose of this study is to evaluate the safety and immune response to an HIV clade C vaccine and to an MF59- or alum-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.
- Trial name
- HVTN107 (NCT03284710)
- Testing
- ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
- Where
- 6 sites in Mozambique, South Africa and 1 more
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Malaria
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
- Trial name
- NCT04675931
- Testing
- Cipargamin, IV Artesunate, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Depression, Adolescent Behavior
Adolescent Depression Screening and Treatment in Mozambican Primary Care
This is a cluster-randomized pilot trial of depression screening and treatment implementation at four Youth-friendly Health Services (YFHS) in primary care clinics, two in Maputo City and two in Maputo Province.
- Trial name
- NCT05476237
- Testing
- Group Interpersonal Therapy for Adolescents (IPT-AG), Treatment as Usual (TAU)
- Where
- 4 sites in Mozambique
- Volunteers
- 95 people
- Sponsor
- Columbia University
Hiv
Estamos Juntos (We Are Together): Improving HIV Care Delivery by Capacitating Health Care Providers
Health care workers' negative behavior towards patients (likely a reflection of low job satisfaction, frustration with delivering HIV care and treatment in extremely resource-limited settings, and burnout) is one of the primary…
- Trial name
- NCT05938621
- Testing
- behavioral therapy and education
- Where
- Mozambique
- Volunteers
- 28,448 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Acute Malaria
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.
- Trial name
- NCT05689047
- Testing
- M5717 330 mg, M5717 500 mg, M5717 660 mg
- Where
- 5 sites in Burkina Faso, Gabon and 2 more
- Volunteers
- 38 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany